Group 1: Jiangzhong Pharmaceutical - Jiangzhong Pharmaceutical's flagship product, Jianwei Digestive Tablets, has achieved cumulative sales of over 5 billion boxes and has been the top-selling OTC digestive medicine in China for 21 consecutive years [20][21] - The company aims to enhance quality through innovation, focusing on three main business areas: OTC products, health consumer goods, and prescription drugs, achieving a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [20][21] - The company has implemented smart manufacturing technologies, achieving over 95% automation in its production processes, significantly improving efficiency and reducing labor costs [22][23] Group 2: Technological Innovation - Jiangzhong Pharmaceutical has developed a unique MVR concentration technology that enhances the extraction efficiency of active ingredients from traditional Chinese medicine to over 90% [22] - The company has established a national key laboratory for modern Chinese medicine creation, focusing on the innovative transformation of classic formulas into modern products [24] - The introduction of innovative flavors and purification techniques has transformed traditional herbal medicines into more palatable products, appealing to a broader consumer base [25] Group 3: Cultural Integration and Market Expansion - Jiangzhong Pharmaceutical has launched a "Healthy Hot Pot" concept that incorporates traditional medicinal ingredients, aiming to modernize and popularize traditional Chinese medicine among younger consumers [26][27] - The company plans to continue expanding its cultural outreach and application of traditional Chinese medicine through various channels, including tourism and dining [27] Group 4: Fushite Company - Fushite has positioned itself in the hydraulic pipeline sector, with a strategic focus on the mining after-market, anticipating a market size of $19.33 billion by 2030 [28][30] - The company has established a comprehensive service system that includes industrial maintenance and heavy spare parts supply, expanding its service capabilities beyond just hydraulic pipeline repairs [32] Group 5: Naipu Mining Machinery - Naipu Mining Machinery has developed a global service network covering over 50 countries, focusing on wear-resistant materials and mining machinery [34][36] - The company has successfully transitioned from basic spare parts production to advanced wear-resistant materials, leveraging new material technologies to enhance product performance [35][36] - Naipu's international strategy includes establishing production bases in Peru to meet the growing demand for mining equipment and spare parts in South America [39][40] Group 6: Sanxin Medical - Sanxin Medical has transformed from a traditional infusion and injection company to a significant player in the blood purification medical device sector, achieving a CAGR of 29.82% in net profit over the past five years [42][45] - The company has expanded its product offerings in blood purification, with revenue from this segment increasing from 20% in 2015 to 81% in 2024 [45] - Sanxin Medical is actively pursuing global market expansion, with overseas revenue growing by 39.70% in 2024, indicating a strong international presence [48][49]

证券代码：688161 证券简称：威高骨科 公告编号：2025-044 山东威高骨科材料股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、议案名称：《关于公司拟聘请会计师事务所的议案》 本次股东会由董事会召集，采用现场投票和网络投票相结合的方式召开，会议由董事长陈敏女士主持， 本次会议的召集、召开方式符合《公司法》、《证券法》、《公司章程》的规定。 （五）公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、董事会秘书林青女士出席会议； 3、公司高管、见证律师列席本次会议。 二、议案审议情况 （一）非累积投票议案 审议结果：通过 表决情况： ■ （二）涉及重大事项，应说明5%以下股东的表决情况 ■ （三）关于议案表决的 ...

CANADA - 2025/11/05: In this photo illustration, the Zimmer Biomet logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesZimmer Biomet (ZBH) could be a strong choice for your investment portfolio, due to its high cash yield, solid fundamentals, and discounted valuation. Companies like this have the capacity to leverage cash for additional revenue growth or to reward their shareholders through divid ...

证券日报网讯利德曼（300289）11月17日在互动平台回答投资者提问时表示，截至2025年11月10日收 盘，公司股东人数为33，374户。 ...

体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 以下文章来源于体重管理三年行动 ，作者体重管理三年行动 波士顿科学的Endura减重解决方案包含一系列减重程序，主要有内窥镜套管胃成形术(ESG)和使用Orbera胃内球囊系统的内窥镜胃内球囊植 入。这两种手术均无需外部切口，不留疤痕，旨在减少胃容量，使患者进食量减少，更快产生饱腹感并维持更长时间。 ESG手术中，内窥镜尖端装有专用缝合装置——OverStitch内窥镜缝合系统，经麻醉患者口腔进入胃部。随后从内部缝合胃壁，将胃容量减少 70%-80%，帮助患者少量进食即可产生持久饱腹感。 胃内球囊植入过程中，一个未充气的球囊经口腔放置于胃内，随后注入无菌生理盐水至约葡萄柚大小，占据胃腔空间，使患者迅速产生饱腹感 并延长满足感。六个月后通过类似简单程序将球囊取出。 临床研究表明，接受ESG手术的患者通常手术当天即可回家，2-3天内恢复日常活动。同样，Orbera球囊通常在门诊完成植入，患者几天至一周 内即可恢复正常生活。临床证据显示，结合生活方式改变(包括健康饮食与运动)，这些方法能有效实现减重目标。 波士顿 ...

证券之星消息，截至2025年11月17日收盘，开立医疗(300633)报收于29.15元，上涨0.83%，换手率 0.81%，成交量3.52万手，成交额1.03亿元。 11月17日的资金流向数据方面，主力资金净流入326.8万元，占总成交额3.18%，游资资金净流出353.63 万元，占总成交额3.44%，散户资金净流入26.83万元，占总成交额0.26%。 近5日资金流向一览见下表： | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 126.14亿元 | 114.59亿元 | 24 124 | | 净资产 | 31.19亿元 | 38.93亿元 | 46 124 | | 净利润 | 3351.11万元 | 2.12亿元 | 74 124 | | 市盈率(动) | 282.3 | 55.42 | 87 124 | | 市净率 | 4.04 | 4.09 | 92 124 | | 毛利率 | 60.36% | 51.22% | 50 124 | | 净利率 | 2.3% | 9.57% | 88 124 | | ROE | 1.0 ...

瑞士媒体认为，尽管关税下调，但面对充满不确定性的特朗普政府，美瑞贸易关系仍然存在不小的变 数。 转载请注明央视财经 美国与瑞士达成贸易谈判框架协议，其背后离不开瑞士企业的积极游说和巨额投资承诺。11月初，嘉能 可、罗氏、诺华等多家瑞士大型企业高管自发组团，赴美与美国总统特朗普会面。为打破僵局，瑞士企 业代表团还带去了刻字金条和劳力士时钟作为礼物，为贸易谈判按下了加速键。会晤后，特朗普直接下 令美国贸易代表格里尔加快与瑞士的谈判进程。本月13日，瑞士联邦委员兼经济和教研部长帕姆兰率团 赴华盛顿与格里尔举行贸易谈判。数小时后，双方宣布达成贸易协议，缓解了瑞士出口企业面临的压 力。 但为了换取关税下调，瑞士付出了沉重代价。作为框架协议的一部分，瑞士企业承诺对美投资2000亿美 元，其中2026年投资额将达670亿美元。投资涵盖制药、医疗器械、航空航天、黄金冶炼等核心产业， 多家瑞士企业承诺将在美国建立生产线。此外，瑞士需进一步开放农产品市场并降低对美农产品关税， 同时承诺减少非关税壁垒、简化检验程序、承认美国车辆安全标准等。 （央视财经《天下财经》）美国白宫网站14日发布美国与瑞士贸易谈判框架协议联合声明。根据声明 ...

10月，A股上市公司回购事项继续平稳推进。 每经资本眼研究员统计发现，10月共有24家公司发布回购预案，多家公司逐渐将回购纳入常态化运作， 年内推出两期回购方案；同时"方案披露即迅速落地"成为10月新亮点，多家公司回购方案执行速度较 快，将回购作为维护市值的重要手段。正在实施回购的公司中，美的集团继续领衔单月回购之最，连续 两个月单月回购超20亿元。 拟回购额环比增长较多 据同花顺iFinD数据统计，10月共有24家公司发布新的回购预案公告，数量与9月的22家基本持平，但拟 回购规模增长较多。以公告数据为准，这24家公司的拟回购金额上限合计约66.5亿元，较9月份的39.69 亿元，环比增加67.55%；其中超过1亿元（含）的有13家，占比54.17%。 从发行人企业性质看，中远海控、中工国际两家央企位列其中。拟回购金额上限居前的公司有：海大集 团、中远海控、中控技术、九安医疗和恒铭达等，分别为16亿元、14.98亿元、10亿元、6亿元和4亿 元。 同时，每经资本眼研究员在上述24家公司中发现了不少"熟面孔"。奥比中光、九安医疗、中远海控、富 士莱、民生健康等公司10月发布的均是年内第二期方案，之江生物更是推 ...

Core Viewpoint - The resumption of the fifth set of IPO standards on the Sci-Tech Innovation Board has led to significant developments for innovative medical device companies, with Shenzhen Core Medical Technology Co., Ltd. being the first to have its IPO application accepted under these new standards, focusing on artificial hearts [1][2]. Company Overview - Core Medical specializes in artificial hearts, reporting a revenue of 94 million yuan in 2024, which represents a growth of over 400% year-on-year, despite a net loss of 132 million yuan during the same period [1]. - The revenue surge is attributed to the successful market launch of its magnetic levitation implantable left ventricular assist device, Corheart® 6, which has generated substantial income [1][4]. Product Details - Corheart® 6 is the first commercially available third-generation magnetic levitation artificial heart, recognized for being the smallest and lightest of its kind globally, weighing only 0.8 kg, which is nearly 50% lighter than its competitor, Abbott's HeartMate 3 [3][4]. - The production cost of Corheart® 6 is approximately 70,000 yuan per unit, with a selling price of 247,200 yuan, resulting in a gross margin close to 70% [9]. Market Challenges - The high price of Corheart® 6, along with the overall surgical costs reaching up to 700,000 yuan, limits the affordability for many patients in China, posing a challenge for its commercialization [1][9]. - Core Medical faces competition not only from Abbott but also from domestic companies like Tongxin Medical and Aerospace Taiheart, which have already launched their products [6][11]. International Expansion - To expand its market, Core Medical aims to penetrate overseas markets, particularly the U.S., where it has yet to initiate clinical trials for Corheart® 6, although it has received approvals in Colombia and Ukraine [6][7]. - The company has other products, such as DuoCor® 2 and CorVad® 4.0/6.0, which are expected to gain approval in the U.S. by 2030, indicating a longer timeline for revenue realization [7]. Industry Landscape - The global heart failure market is projected to grow, with the number of heart failure patients expected to rise from 62.98 million in 2024 to 71.51 million by 2033, presenting a significant opportunity for artificial heart technologies [11]. - However, the emergence of alternative therapies, such as minimally invasive atrial shunt devices, poses additional competition for artificial heart products [11].

证券之星消息，截至2025年11月17日收盘，可孚医疗(301087)报收于42.97元，下跌1.24%，换手率 0.85%，成交量1.66万手，成交额7106.23万元。 11月17日的资金流向数据方面，主力资金净流出67.74万元，占总成交额0.95%，游资资金净流出384.99 万元，占总成交额5.42%，散户资金净流入452.73万元，占总成交额6.37%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-17 | 42.97 | -1.24% | -67.74万 | -0.95% | -384.99万 | -5.42% | 452.73万 | - 6.37% | | 2025-11-14 | 43.51 | -1.40% | -979.22万 | -17.72% | 129.65万 | 2.35% | 849.56万 | 15.37% | | 2025-11-13 | ...